Results 21 to 30 of about 163,967 (239)
Updates on precision medicine of pancreatic neuroendocrine tumor [PDF]
Zhongguo aizheng zazhi, 2023 Since the concept of precision medicine proposed in 2011, the treatment of solid tumors has entered era of precision medicine led by gene testing. As a rare tumor, the incidence rate of pancreatic neuroendocrine tumor (PanNET) is increasing gradually. In
GAO Heli, XU Jin, CHEN Jie, YU Xianjun
doaj +1 more source
BMC Cancer, 2020 Background There are several treatment modalities for unresectable neuroendocrine tumors. Traditionally, the aim of these treatments has been to reduce the tumor load; referred to as objective response (OR).
Espen Thiis-Evensen +3 more
doaj +1 more source
Neuroendocrine Tumors of the Lung [PDF]
Cancers, 2012 Neuroendocrine tumors may develop throughout the human body with the majority being found in the gastrointestinal tract and bronchopulmonary system. Neuroendocrine tumors are classified according to the grade of biological aggressiveness (G1–G3) and the extent of differentiation (well-differentiated/poorly-differentiated).
Annette Fisseler-Eckhoff, Melanie Demes
openaire +3 more sources
Frontiers in Endocrinology, 2022 BackgroundTumor grade determined by the Ki67 index is the best prognostic factor for pancreatic neuroendocrine tumors (PanNETs). However, we often observe that the grade of metastases differs from that of their primary tumors.
Wu-Hu Zhang +60 more
doaj +1 more source
Pharmaceuticals, 2021 The carcinoid syndrome (CS) and hyperinsulinemic hypoglycemia (HH) represent two of the most common clinical syndromes associated with neuroendocrine neoplasms (NENs).
Francesca Spada +8 more
doaj +1 more source
Clinical study of robot and laparoscopic minimally invasive surgery for well-differentiated pancreatic neuroendocrine tumors [PDF]
Zhongguo aizheng zazhi, 2022 Background and purpose: Pancreatic neuroendocrine tumor (pNET) is a rare tumor. At present, there is still a lack of large-scale clinical research data to summarize the clinical effect of minimally invasive technology in the treatment of pNET. This study
LIU Wensheng, JI Shunrong, ZHUO Qifeng, GAO Heli, SHI Yihua, XU Wenyan, LIU Mengqi, LI Zheng, YU Xianjun, CHEN Jie, XU Xiaowu
doaj +1 more source
Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future [PDF]
, 2019 In recent decades, the incidence of neuroendocrine tumors (NETs) has steadily increased. Due to the slow-growing nature of these tumors and the lack of early symptoms, most cases are diagnosed at advanced stages, when curative treatment options are no ...
Amthauer, Holger +8 more
core +1 more source
Frontiers in Oncology, 2022 BackgroundThe four major pathways in gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) including chromatin remodeling, DNA damage repair, activation of mTOR signaling, and telomere maintenance were mediated by some critical molecules and ...
Xin Lou +51 more
doaj +1 more source
Collision of ductal adenocarcinoma and neuroendocrine tumor of the pancreas: a case report and review of the literature [PDF]
, 2017 Background: Simultaneous occurrence of exocrine and neuroendocrine tumors of the pancreas is very infrequent. We report a patient with an endocrine tumor in the pancreatic-duodenal area and extensive exocrine carcinoma involving the whole pancreas.
Blandamura, Stella +6 more
core +2 more sources
Tumor size and perineural invasion predict outcome of gastric high-grade neuroendocrine neoplasms
Endocrine Connections, 2021 A new subcategory, grade 3 neuroendocrine tumors, is incorporated into the grading system of pancreatic neuroendocrine neoplasms in the 2017 WHO c lassification in order to differentiate grade 3 neuroendocrine tumors from neuroendocri ne carcinomas.
Qi Zhang +14 more
doaj +1 more source